Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18398984 | 1.00 | PDE4B (0.43) | PDE4BPIK3CDPIK3CAGPR119 | |
| SCHEMBL21796807 | 1.00 | PDE4B (0.43) | PDE4BPIK3CDPIK3CAGPR119 | |
| SCHEMBL21796806 | 1.00 | PDE4B (0.43) | PDE4BPIK3CDPIK3CAGPR119 | |
| SCHEMBL21796648 | 1.00 | PDE4B (0.43) | PDE4BPIK3CDPIK3CAGPR119 | |
| SCHEMBL21796698 | 0.96 | PDE4B (0.43) | PDE4BPIK3CDPIK3CAGPR119 | |
| SCHEMBL18399047 | 0.96 | PDE4B (0.43) | PDE4BPIK3CDPIK3CAGPR119 | |
| SCHEMBL18398970 | 0.96 | PDE4B (0.43) | PDE4BPIK3CDPIK3CAGPR119 | |
| SCHEMBL21797080 | 0.96 | PDE4B (0.43) | PDE4BPIK3CDPIK3CAGPR119 | |
| SCHEMBL18399075 | 0.94 | RXRA (0.41) | PDE4BPIK3CDGPR119 | |
| SCHEMBL21797117 | 0.89 | RXRA (0.44) | PDE4BPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137510-B | Compound (I) | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| US-20200079777-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
| EP-3325449-A1 | COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017012576-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | PDE4B 1409/4885PIK3CD 424/4885PIK3CA 449/4885 |
| US-20200079777-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | PDE4B 2282/4885PIK3CD 668/4885PIK3CA 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.